Recombinant glycoproteins: The impact of cell lines and culture conditions on the generation of protein species

Journal of Proteomics

Volumn 134, Issue , 2016, Pages 85-92

  Rosenlöcher, Julia ^a,b   Sandig, Grit ^a   Kannicht, Christoph ^c   Blanchard, Véronique ^d   Reinke, Stefan O ^a   Hinderlich, Stephan ^a  

^a BEUTH UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c Octapharma Biopharmaceuticals GmbH   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Glycoform; Glycoprotein species; Microheterogeneity; N glycosylation; Protein species; Recombinant glycoprotein

Indexed keywords

RECOMBINANT ALPHA 1 ANTITRYPSIN; RECOMBINANT ANTIBODY; RECOMBINANT IMMUNOGLOBULIN G1 ANTIBODY; RECOMBINANT PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; ALPHA 1 ANTITRYPSIN;

ANIMAL CELL; ARTICLE; CARBOHYDRATE ANALYSIS; CHO CELL LINE; CONTROLLED STUDY; DERIVATIZATION; EMBRYO; FEMALE; GLYCOSYLATION; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN METHYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SPECIES CULTIVATION; BIOSYNTHESIS; CELL CULTURE TECHNIQUE; GENETICS; HEK293 CELL LINE; PROCEDURES;

ALPHA 1-ANTITRYPSIN; CELL CULTURE TECHNIQUES; GLYCOSYLATION; HEK293 CELLS; HUMANS; RECOMBINANT PROTEINS;

EID: 84958182305     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.08.011     Document Type: Article

References (51)

1. Jungblut P., Thiede B., Zimny-Arndt U., Muller E.C., Scheler C., Wittmann-Liebold B., Otto A. Resolution power of two-dimensional electrophoresis and identification of proteins from gels. Electrophoresis 1996, 17:839-847.
2. Jungblut P.R., Holzhutter H.G., Apweiler R., Schluter H. The speciation of the proteome. Chem. Cent. J. 2008, 2:16.
3. Ohtsubo K., Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126:855-867.
4. Dennis R.P. A review of the biological significance of carbohydrates on glycoproteins and methods for their analysis. Glycoimmunology 1995, 1-11. Plenum Press, New York. A. Alavi, J.S. Axford (Eds.).
5. Jenkins N., Parekh R.B., James D.C. Getting the glycosylation right: implications for the biotechnology industry. Nat. Biotechnol. 1996, 14:975-981.
6. Jones J., Krag S.S., Betenbaugh M.J. Controlling N-linked glycan site occupancy. Biochim. Biophys. Acta 2005, 1726:121-137.
7. Rademacher T.W., Parekh R.B., Dwek R.A. Glycobiology. Annu. Rev. Biochem. 1988, 57:785-838.
8. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277:26733-26740.
9. Morell A.G., Gregoriadis G., Scheinberg I.H., Hickman J., Ashwell G. The role of sialic acid in determining the survival of glycoproteins in the circulation. J. Biol. Chem. 1971, 246:1461-1467.
10. Weiss P., Ashwell G. The asialoglycoprotein receptor: properties and modulation by ligand. Prog. Clin. Biol. Res. 1989, 300:169-184.
11. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr. Opin. Struct. Biol. 2009, 19:507-514.
12. Varki A., Gagneux P. Multifarious roles of sialic acids in immunity. Ann. N. Y. Acad. Sci. 2012, 1253:16-36.
13. Ghaderi D., Zhang M., Hurtado-Ziola N., Varki A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol. Genet. Eng. Rev. 2012, 28:147-175.
14. Walsh G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 2006, 24:769-776.
15. Parekh R.B., Dwek R.A., Rudd P.M., Thomas J.R., Rademacher T.W., Warren T., Wun T.C., Hebert B., Reitz B., Palmier M., et al. N-glycosylation and in vitro enzymatic activity of human recombinant tissue plasminogen activator expressed in Chinese hamster ovary cells and a murine cell line. Biochemistry 1989, 28:7670-7679.
16. Parekh R.B., Dwek R.A., Thomas J.R., Opdenakker G., Rademacher T.W., Wittwer A.J., Howard S.C., Nelson R., Siegel N.R., Jennings M.G., et al. Cell-type-specific and site-specific N-glycosylation of type I and type II human tissue plasminogen activator. Biochemistry 1989, 28:7644-7662.
17. Fukuda M.N., Sasaki H., Lopez L., Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 1989, 73:84-89.
18. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21-50.
19. Carrell R.W., Jeppsson J.O., Vaughan L., Brennan S.O., Owen M.C., Boswell D.R. Human alpha 1-antitrypsin: carbohydrate attachment and sequence homology. FEBS Lett. 1981, 135:301-303.
20. von Horsten H.H., Ogorek C., Blanchard V., Demmler C., Giese C., Winkler K., Kaup M., Berger M., Jordan I., Sandig V. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-d-lyxo-4-hexulose reductase. Glycobiology 2010, 20:1607-1618.
21. Reinke S.O., Bayer M., Berger M., Blanchard V., Hinderlich S. Analysis of cell surface N-glycosylation of the human embryonic kidney 293T cell line. J. Carbohydr. Chem. 2011, 30:218-232.
22. Wada Y., Azadi P., Costello C.E., Dell A., Dwek R.A., Geyer H., Geyer R., Kakehi K., Karlsson N.G., Kato K., Kawasaki N., Khoo K.H., Kim S., Kondo A., Lattova E., Mechref Y., Miyoshi E., Nakamura K., Narimatsu H., Novotny M.V., Packer N.H., Perreault H., Peter-Katalinic J., Pohlentz G., Reinhold V.N., Rudd P.M., Suzuki A., Taniguchi N. Comparison of the methods for profiling glycoprotein glycans-HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology 2007, 17:411-422.
23. Dell A., Khoo K.-H., Panico M., McDowell R.A., Etienne A.T., Reason A.J., Morris H.R. Glycobiology: a Practical Approach 1993, 187-222. IRL Press at Oxford University Press, Oxford. M. Fukuda, A. Kobata (Eds.).
24. Frisch E., Kaup M., Egerer K., Weimann A., Tauber R., Berger M., Blanchard V. Profiling of Endo H-released serum N-glycans using CE-LIF and MALDI-TOF-MS-application to rheumatoid arthritis. Electrophoresis 2011, 32:3510-3515.
25. Varki A., Cummings R.D., Esko J.D., Freeze H.H., Stanley P., Marth J.D., Bertozzi C.R., Hart G.W., Etzler M.E. Symbol nomenclature for glycan representation. Proteomics 2009, 9:5398-5399.
26. Huhn C., Selman M.H., Ruhaak L.R., Deelder A.M., Wuhrer M. IgG glycosylation analysis. Proteomics 2009, 9:882-913.
27. Flynn G.C., Chen X., Liu Y.D., Shah B., Zhang Z. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol. Immunol. 2010, 47:2074-2082.
28. Stanley P., Raju T.S., Bhaumik M. CHO cells provide access to novel N-glycans and developmentally regulated glycosyltransferases. Glycobiology 1996, 6:695-699.
29. Xu X., Nagarajan H., Lewis N.E., Pan S., Cai Z., Liu X., Chen W., Xie M., Wang W., Hammond S., Andersen M.R., Neff N., Passarelli B., Koh W., Fan H.C., Wang J., Gui Y., Lee K.H., Betenbaugh M.J., Quake S.R., Famili I., Palsson B.O., Wang J. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat. Biotechnol. 2011, 29:735-741.
30. Goetze A.M., Liu Y.D., Zhang Z., Shah B., Lee E., Bondarenko P.V., Flynn G.C. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011, 21:949-959.
31. Shade K.-T.C., Anthony R.M. Antibody glycosylation and inflammation. Antibodies 2013, 2:392-414.
32. Ogorek C., Jordan I., Sandig V., von Horsten H.H. Fucose-targeted glycoengineering of pharmaceutical cell lines. Methods Mol. Biol. 2012, 907:507-517.
33. Konno Y., Kobayashi Y., Takahashi K., Takahashi E., Sakae S., Wakitani M., Yamano K., Suzawa T., Yano K., Ohta T., Koike M., Wakamatsu K., Hosoi S. Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity. Cytotechnology 2011, 64:249-265.
34. Anthony R.M., Ravetch J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 2010, 30(Suppl. 1):S9-S14.
35. Finotti P., Pagetta A. Albumin contamination of a purified human alpha 1-antitrypsin preparation does not affect either structural conformation or the electrophoretic mobility of the inhibitor. Clin. Chim. Acta 1997, 264:133-148.
36. Reh G., Nerli B., Pico G. Isolation of alpha-1-antitrypsin from human plasma by partitioning in aqueous biphasic systems of polyethyleneglycol-phosphate. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2002, 780:389-396.
37. Lusch A., Kaup M., Marx U., Tauber R., Blanchard V., Berger M. Development and analysis of alpha 1-antitrypsin neoglycoproteins: the impact of additional N-glycosylation sites on serum half-life. Mol. Pharm. 2013, 10:2616-2629.
38. Reinke S.O., Bayer M., Berger M., Hinderlich S., Blanchard V. The analysis of N-glycans of cell membrane proteins from human hematopoietic cell lines reveals distinctions in their pattern. Biol. Chem. 2012, 393:731-747.
39. Lin Y.C., Boone M., Meuris L., Lemmens I., Van Roy N., Soete A., Reumers J., Moisse M., Plaisance S., Drmanac R., Chen J., Speleman F., Lambrechts D., Van de Peer Y., Tavernier J., Callewaert N. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat. Commun. 2014, 5:4767.
40. Kolarich D., Weber A., Turecek P.L., Schwarz H.P., Altmann F. Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin and its charge isoforms. Proteomics 2006, 6:3369-3380.
41. Ayoub D., Jabs W., Resemann A., Evers W., Evans C., Main L., Baessmann C., Wagner-Rousset E., Suckau D., Beck A. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs 2013, 5:699-710.
42. Fregonese L., Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J. Rare Dis. 2008, 3:16.
43. Tirado-Conde G., Lara B., Miravitlles M. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency. Ther. Adv. Respir. Dis. 2008, 2:13-21.
44. Karnaukhova E., Ophir Y., Golding B. Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids 2006, 30:317-332.
45. Canis K., McKinnon T.A., Nowak A., Haslam S.M., Panico M., Morris H.R., Laffan M.A., Dell A. Mapping the N-glycome of human von Willebrand factor. Biochem. J. 2012, 447:217-228.
46. Canis K., McKinnon T.A., Nowak A., Panico M., Morris H.R., Laffan M., Dell A. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J. Thromb. Haemost. 2010, 8:137-145.
47. Aebi M. N-linked protein glycosylation in the ER. Biochim. Biophys. Acta 2013, 1833:2430-2437.
48. Gawlitzek M., Valley U., Nimtz M., Wagner R., Conradt H.S. Characterization of changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due to different culture conditions. J. Biotechnol. 1995, 42:117-131.
49. Gawlitzek M., Ryll T., Lofgren J., Sliwkowski M.B. Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms. Biotechnol. Bioeng. 2000, 68:637-646.
50. Pacis E., Yu M., Autsen J., Bayer R., Li F. Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform. Biotechnol. Bioeng. 2011, 108:2348-2358.
51. Rosenlöcher J., Weilandt C., Sandig G., Reinke S.O., Blanchard V., Hinderlich S. The human rhabdomyosarcoma cell line TE671 - towards an innovative production platform for glycosylated biopharmaceuticals. Protein Expr. Purif. 2015, [Epub ahead of print]. 10.1016/j.pep.2015.08.008.